AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Global Vaccine Adjuvants Market Report, 2019: Analysis & Forecast Through 2017-2026 - ResearchAndMarkets.com

February 21, 2019

DUBLIN--(BUSINESS WIRE)--Feb 21, 2019--The “Vaccine Adjuvants - Global Market Outlook (2017-2026)” report has been added to ResearchAndMarkets.com’s offering.

According to this report, the Global Vaccine Adjuvants market accounted for $460.21 million in 2017 and is expected to reach $1,330.25 million by 2026 growing at a CAGR of 12.5% from 2017 to 2026.

Some of the factors such as the high occurrence of zoonotic and infectious syndromes, growing geriatric population and rising usage of Adjuvants in Vaccine are fueling the market growth. However, factors such as the cost of adjuvant development and side effects of adjuvants are hampering the market growth. The rising usage of synthetic vaccines and recombinant sub-unit are acting as an opportunity for the market growth in the coming years.

Amongst Route of Administration, Intramuscular Route segment is driven by owing to rapidly rising geriatric population and vaccines for enhanced immunization are propelling the growth of this segment. These include vaccines for HPV, influenza, meningitis, etc.

By geography, North America region is dominated the market during the forecast period due to factors such as higher adoption, greater knowledge about regular vaccination and presence of major market players, coupled with higher healthcare expenditure.

What the report offers:

Topics Covered

1 Executive Summary

2 Preface

2.1 Abstract

2.2 Stake Holders

2.3 Research Scope

2.4 Research Methodology

2.4.1 Data Mining

2.4.2 Data Analysis

2.4.3 Data Validation

2.4.4 Research Approach

2.5 Research Sources

2.5.1 Primary Research Sources

2.5.2 Secondary Research Sources

2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Product Analysis

3.7 Application Analysis

3.8 End User Analysis

3.9 Emerging Markets

3.10 Futuristic Market Scenario

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Vaccine Adjuvants Market, By Product

5.1 Introduction

5.2 Pathogen Components

5.3 Particulate Adjuvants

5.4 Combination Adjuvants

5.5 Adjuvant Emulsions

5.6 Saponin

5.7 Other Types

6 Global Vaccine Adjuvants Market, By Disease Type

6.1 Introduction

6.2 Cancer

6.3 Infectious Diseases

6.4 Other Disease Types

7 Global Vaccine Adjuvants Market, By Type

7.1 Introduction

7.2 Virus-like Particles

7.3 Tensoactive Adjuvants

7.4 Organic Adjuvants

7.5 Mineral Salt based Adjuvants

7.6 Liposomes

7.7 Emulsions

7.8 Carbohydrates Adjuvants

7.9 Bacteria-derived Adjuvants

7.10 Other Types

8 Global Vaccine Adjuvants Market, By Mechanism of action

8.1 Introduction

8.2 Vehicle Adjuvants

8.3 Carriers

8.4 Active Immunostimulants

9 Global Vaccine Adjuvants Market, By Route of Administration

9.1 Introduction

9.2 Subcutaneous Route

9.3 Oral Route

9.4 Intranasal Route

9.5 Intramuscular Route

9.6 Intradermal Route

9.7 Other Route of Administrations

10 Global Vaccine Adjuvants Market, By Application

10.1 Introduction

10.2 Veterinary Vaccine Adjuvants

10.3 Human Vaccine Adjuvants

11 Global Vaccine Adjuvants Market, By End User

11.1 Introduction

11.2 Research Institutes

11.3 Pharmaceutical Companies

11.4 Contract Manufacturing Organization

11.5 Commercial

11.6 Pediatric

11.7 Adults

11.8 Other End Users

12 Global Vaccine Adjuvants Market, By Geography

12.1 Introduction

12.2 North America

12.2.1 US

12.2.2 Canada

12.2.3 Mexico

12.3 Europe

12.3.1 Germany

12.3.2 UK

12.3.3 Italy

12.3.4 France

12.3.5 Spain

12.3.6 Rest of Europe

12.4 Asia Pacific

12.4.1 Japan

12.4.2 China

12.4.3 India

12.4.4 Australia

12.4.5 New Zealand

12.4.6 South Korea

12.4.7 Rest of Asia Pacific

12.5 South America

12.5.1 Argentina

12.5.2 Brazil

12.5.3 Chile

12.5.4 Rest of South America

12.6 Middle East & Africa

12.6.1 Saudi Arabia

12.6.2 UAE

12.6.3 Qatar

12.6.4 South Africa

12.6.5 Rest of Middle East & Africa

13 Key Developments

13.1 Agreements, Partnerships, Collaborations and Joint Ventures

13.2 Acquisitions & Mergers

13.3 New Product Launch

13.4 Expansions

13.5 Other Key Strategies

14 Company Profiling

14.1 Viscogel AB

14.2 Vaxliant

14.3 Vaxine Pty Ltd.

14.4 Sigma Aldrich (Merck KGaA)

14.5 Sergeant Adjuvants

14.6 OZ Biosciences

14.7 Novavax, Inc.

14.8 Novartis/CSL

14.9 MVP Laboratories, Inc.

14.10 Kineta, Inc.

14.11 Invivogen

14.12 GSK

14.13 CureVac AG

14.14 CSL Limited

14.15 Avanti Polar Lipids

14.16 Aphios Corp.

14.17 Agenus, Inc.

14.18 Adjuvatis

14.19 Adjuvance Technologies, Inc

For more information about this report visit https://www.researchandmarkets.com/research/848kpq/global_vaccine?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005845/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/21/2019 02:33 PM/DISC: 02/21/2019 02:33 PM

http://www.businesswire.com/news/home/20190221005845/en